Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report

01 - Pre-Meeting Briefing

02 - Submission from the technology manufacturer – Astellas

03 - NICE request to the manufacturer for clarification on their submission

04 - Manufacturer clarification response

05 - Consultee submission – Prostate Cancer UK

06 - Consultee submission – Prostate Cancer Support Federation

07 - Consultee submission – British Uro-Oncology Group

08 - Consultee submission – Royal College of Physicians

09 - Clinical expert personal perspective - Bahl

10 - Clinical expert personal perspective - Russell

11 - Patient expert personal perspective - Gunn

12 - Patient expert personal perspective – Watson

13 - Evidence Review Group report prepared by Kleijnen Systematic Reviews

14 - Manufacturer factual accuracy check of Evidence Review Group report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *

This page was last updated: 17 October 2013